<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096744</url>
  </required_header>
  <id_info>
    <org_study_id>253.2486</org_study_id>
    <nct_id>NCT02096744</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind Study Designed to Assess the Bioequivalence and Adhesion Properties of Transdermal Clonidine-VistanexTM Compared to Transdermal Clonidine-Oppanol® Following Transdermal Administration in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To establish the bioequivalence and adhesion properties of transdermal clonidine prepared
      with Oppanol® brands of polyisobutylene (PIB) vs. transdermal clonidine prepared with
      VistanexTM brands of polyisobutylene (PIB) in healthy male and female volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-168 (Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to 168 h)</measure>
    <time_frame>1 hour (h) before patch administration and 12h, 24h, 48h, 72h, 96h, 120h, 144h, 168h after patch administration</time_frame>
    <description>AUC0-168 (area under the concentration-time curve of clonidine in plasma over the time interval from 0 to 168 h) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cavg (Average of Measured Concentrations of Clonidine in Plasma on Days 5, 6, and 7)</measure>
    <time_frame>1 hour (h) before patch administration and 12h, 24h, 48h, 72h, 96h, 120h, 144h, 168h, 192h, 216h, 240h after patch administration</time_frame>
    <description>Cavg (average of measured concentrations of clonidine in plasma on Days 5, 6, and 7) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf(Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to Infinity)</measure>
    <time_frame>1 hour (h) before patch administration and 12h, 24h, 48h, 72h, 96h, 120h, 144h, 168h, 192h, 216h, 240h after patch administration</time_frame>
    <description>AUC 0-inf(area under the concentration-time curve of clonidine in plasma over the time interval from 0 to infinity) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum Concentration of Clonidine in Plasma)</measure>
    <time_frame>1 hour (h) before patch administration and 12h, 24h, 48h, 72h, 96h, 120h, 144h, 168h, 192h, 216h, 240h after patch administration</time_frame>
    <description>Cmax (maximum concentration of clonidine in plasma) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Catapres-TTS-3 crossover 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catapres-TTS-3 crossover 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catapres-TTS-1 crossover 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catapres-TTS-1</intervention_name>
    <description>Catapres-TTS-1 Oppanol</description>
    <arm_group_label>Catapres-TTS-1 crossover 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention 1: Catapres-TTS-3</intervention_name>
    <description>Catapres-TTS-3 Oppanol</description>
    <arm_group_label>Catapres-TTS-3 crossover 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention 1: Catapres-TTS-3</intervention_name>
    <description>Catapres-TTS-3 Oppanol</description>
    <arm_group_label>Catapres-TTS-3 crossover 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention 2: Catapres-TTS-3</intervention_name>
    <description>Catapres-TTS-3 Vistanex</description>
    <arm_group_label>Catapres-TTS-3 crossover 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catapres-TTS-1</intervention_name>
    <description>Catapres-TTS-1 Vistanex</description>
    <arm_group_label>Catapres-TTS-1 crossover 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention 2: Catapres-TTS-3</intervention_name>
    <description>Catapres-TTS-3 Vistanex</description>
    <arm_group_label>Catapres-TTS-3 crossover 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. A complete medical history, including the physical examination, vital signs (BP, PR),
             12-lead ECG, clinical laboratory tests

          2. Age greater than or equal to 18 and Age less than or equal to 65 years

          3. BMI greater than or equal to 18.5 and BMI less than or equal to 32.0 kg/m2 (Body Mass
             Index)

          4. Signed and dated written informed consent prior to admission to the study

          5. Male subjects, or females who meet any of the following criteria from at least 30 days
             before the first study drug administration and until 30 days after trial completion:

               -  Using adequate contraception, e.g. any of the following methods plus condom:
                  implants, injectables, combined oral contraceptives, intrauterine device (IUD)

               -  Sexually abstinent

               -  Have a vasectomised sexual partner (vasectomy at least one year prior to
                  enrolment)

               -  Surgically sterilised (including hysterectomy)

               -  Postmenopausal defined as at least one year of spontaneous amenorrhea

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal

          2. Repeated measurement of supine systolic blood pressure outside the range of 100-140 mm
             Hg or diastolic blood pressure outside the range of 60-90 mm Hg or pulse less than 55
             bpm

          3. Any subject with orthostatic hypotension at baseline screening exam

          4. Any laboratory value outside the reference range

          5. Any evidence of a clinically relevant concomitant disease

          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic (including
             insulin-dependent diabetes), immunological or hormonal disorders

          7. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
             (such as depression) or neurological disorders (such as neuropathy)

          8. History of relevant orthostatic hypotension, fainting spells or blackouts

          9. Chronic or relevant acute infections

         10. History of relevant allergy/hypersensitivity

         11. Intake of drugs with a long half-life (greater than 24 hours) within at least one
             month or less than 10 half-lives of the respective drug prior to administration or
             during the trial.

         12. Use of drugs which might reasonably influence the results of the trial within 10 days
             prior to administration or during the trial

         13. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         14. Any concomitant therapy

         15. Smoker

         16. History of alcohol abuse

         17. History of drug abuse

         18. Blood donation

         19. Excessive physical activities (within one week prior to administration or during the
             trial)

         20. Subjects should not swim during the treatment periods of the trial

         21. Any condition of the skin, including eczema, psoriasis, or lymphedema, that involves
             the upper arm in the area that would be utilized for application of the treatments

         22. Pregnancy or planning to become pregnant within two months of study completion

         23. Positive pregnancy test

         24. A screening ECG that displays first-degree atrioventricular block (P-R interval &gt; 0.20
             seconds) or other conduction disturbance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>253.2486.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>June 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2015</results_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in three separate groups.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Catapres®-TTS-3 Crossover 1: TTS-3 Oppanol Then TTS-3 Vistanex</title>
          <description>Catapres®-TTS(Transdermal Therapeutic System)-3 (0.3 mg/24 hr) Oppanol® (T1) first, followed by Catapres®-TTS-3 (0.3 mg/24 hr) Vistanex™ (R1). Followed by simultaneous administration of TTS-1 Oppanol® (T2) and TTS-1 Vistanex™ (R2) patches each delivering 0.1mg clinidine/24h.</description>
        </group>
        <group group_id="P2">
          <title>Catapres®-TTS-3 Crossover 2: TTS-3 Vistanex Then TTS-3 Oppanol</title>
          <description>Catapres®-TTS-3 (0.3 mg/24 hr) Vistanex™ (R1) first, followed by Catapres®-TTS-3 (0.3 mg/24 hr) Oppanol® (T1). Followed by simultaneous administration of TTS-1 Oppanol® (T2) and TTS-1 Vistanex™ (R2) patches each delivering 0.1mg clinidine/24h.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1(7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Accidental early removal of the patch</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance with the site rule</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 1(7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled subjects in the trial were treated and were included in the treated set (TS).</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>A randomised, double-blind, 2-way crossover design, followed by a period for assessment of adhesive properties of the clonidine patch.
In the crossover part of the trial, subjects were treated with either Catapres®-TTS delivering 0.3 mg clonidine/24 h (TTS-3) in the Oppanol® formulation (test treatment T1) or Catapres®-TTS-3 (0.3 mg/24 h) with Vistanex™ formulation (reference treatment R1) in each period. In the adhesion phase of the trial, subjects were treated simultaneously with Oppanol® (test treatment T2) and Vistanex™ (reference treatment R2) patches, each delivering 0.1 mg clonidine/24 h (TTS-1).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-168 (Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to 168 h)</title>
        <description>AUC0-168 (area under the concentration-time curve of clonidine in plasma over the time interval from 0 to 168 h) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
        <time_frame>1 hour (h) before patch administration and 12h, 24h, 48h, 72h, 96h, 120h, 144h, 168h after patch administration</time_frame>
        <population>PKS included all treated subjects who provided at least one observation for at least one primary endpoint without protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Catapres®-TTS-3 With Oppanol®</title>
            <description>Subject to receive 0.3 mg/24 hr Catapres®-TTS-3 Oppanol® (T1)</description>
          </group>
          <group group_id="O2">
            <title>Catapres®-TTS-3 With Vistanex™</title>
            <description>Subject to receive 0.3 mg/24 hr Catapres®-TTS-3 Vistanex™ (R1)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-168 (Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to 168 h)</title>
          <description>AUC0-168 (area under the concentration-time curve of clonidine in plasma over the time interval from 0 to 168 h) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
          <population>PKS included all treated subjects who provided at least one observation for at least one primary endpoint without protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82517.99" spread="19.0"/>
                    <measurement group_id="O2" value="80641.47" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratios of the geometric means Catapres-TTS-3(Oppanol/Vistanex) using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on the logarithmic scale including effects for 'Group', ‘sequence’, ‘subjects within sequences’, ‘period’, and ‘treatment’.</method_desc>
            <param_type>Adjusted Geometric Mean ratio</param_type>
            <param_value>102.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.74</ci_lower_limit>
            <ci_upper_limit>109.37</ci_upper_limit>
            <estimate_desc>The estimated value is actually the ratio of Catapres-TTS-3 with Oppanol and Catapres-TTS-3 with Vistanex.
The value in parameter dispersion type and dispersion value is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cavg (Average of Measured Concentrations of Clonidine in Plasma on Days 5, 6, and 7)</title>
        <description>Cavg (average of measured concentrations of clonidine in plasma on Days 5, 6, and 7) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
        <time_frame>1 hour (h) before patch administration and 12h, 24h, 48h, 72h, 96h, 120h, 144h, 168h, 192h, 216h, 240h after patch administration</time_frame>
        <population>PKS included all treated subjects who provided at least one observation for at least one primary endpoint without protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Catapres®-TTS-3 With Oppanol®</title>
            <description>Subject to receive 0.3 mg/24 hr Catapres®-TTS-3 Oppanol® (T1)</description>
          </group>
          <group group_id="O2">
            <title>Catapres®-TTS-3 With Vistanex™</title>
            <description>Subject to receive 0.3 mg/24 hr Catapres®-TTS-3 Vistanex™ (R1)</description>
          </group>
        </group_list>
        <measure>
          <title>Cavg (Average of Measured Concentrations of Clonidine in Plasma on Days 5, 6, and 7)</title>
          <description>Cavg (average of measured concentrations of clonidine in plasma on Days 5, 6, and 7) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
          <population>PKS included all treated subjects who provided at least one observation for at least one primary endpoint without protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="697.327" spread="16.6"/>
                    <measurement group_id="O2" value="668.893" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratios of the geometric means Catapres-TTS-3(Oppanol/Vistanex) using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on the logarithmic scale including effects for 'Group', ‘sequence’, ‘subjects within sequences’, ‘period’, and ‘treatment’.</method_desc>
            <param_type>Adjusted Geometric Means ratio</param_type>
            <param_value>104.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.367</ci_lower_limit>
            <ci_upper_limit>110.487</ci_upper_limit>
            <estimate_desc>The estimated value is actually the ratio of Catapres-TTS-3 with Oppanol and Catapres-TTS-3 with Vistanex.
The value in parameter dispersion type and dispersion value is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf(Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to Infinity)</title>
        <description>AUC 0-inf(area under the concentration-time curve of clonidine in plasma over the time interval from 0 to infinity) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
        <time_frame>1 hour (h) before patch administration and 12h, 24h, 48h, 72h, 96h, 120h, 144h, 168h, 192h, 216h, 240h after patch administration</time_frame>
        <population>PKS included all treated subjects who provided at least one observation for at least one primary endpoint without protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Catapres®-TTS-3 With Oppanol®</title>
            <description>Subject to receive 0.3 mg/24 hr Catapres®-TTS-3 Oppanol® (T1)</description>
          </group>
          <group group_id="O2">
            <title>Catapres-TTS-3 With Vistanex™</title>
            <description>Subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex™ (R1)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf(Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to Infinity)</title>
          <description>AUC 0-inf(area under the concentration-time curve of clonidine in plasma over the time interval from 0 to infinity) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
          <population>PKS included all treated subjects who provided at least one observation for at least one primary endpoint without protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119127.55" spread="15.8"/>
                    <measurement group_id="O2" value="115903.34" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratios of the geometric means Catapres-TTS-3(Oppanol/Vistanex) using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on the logarithmic scale including effects for 'Group', ‘sequence’, ‘subjects within sequences’, ‘period’, and ‘treatment’.</method_desc>
            <param_type>Adjusted Geometric Means ratio</param_type>
            <param_value>102.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.25</ci_lower_limit>
            <ci_upper_limit>108.63</ci_upper_limit>
            <estimate_desc>The estimated value is actually the ratio of Catapres-TTS-3 with Oppanol and Catapres-TTS-3 with Vistanex.
The value in parameter dispersion type and dispersion value is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Maximum Concentration of Clonidine in Plasma)</title>
        <description>Cmax (maximum concentration of clonidine in plasma) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
        <time_frame>1 hour (h) before patch administration and 12h, 24h, 48h, 72h, 96h, 120h, 144h, 168h, 192h, 216h, 240h after patch administration</time_frame>
        <population>PKS included all treated subjects who provided at least one observation for at least one primary endpoint without protocol violations with respect to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Catapres®-TTS-3 With Oppanol®</title>
            <description>Subject to receive 0.3 mg/24 hr Catapres®-TTS-3 Oppanol® (T1)</description>
          </group>
          <group group_id="O2">
            <title>Catapres®-TTS-3 With Vistanex™</title>
            <description>Subject to receive 0.3 mg/24 hr Catapres®-TTS-3 Vistanex™ (R1)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Concentration of Clonidine in Plasma)</title>
          <description>Cmax (maximum concentration of clonidine in plasma) The values for geometric mean and gCV are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.</description>
          <population>PKS included all treated subjects who provided at least one observation for at least one primary endpoint without protocol violations with respect to the statistical evaluation of PK endpoints.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="813.516" spread="16.7"/>
                    <measurement group_id="O2" value="781.896" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratios of the geometric means Catapres-TTS-3(Oppanol/Vistanex) using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA on the logarithmic scale including effects for 'Group',‘sequence’, ‘subjects within sequences’, ‘period’, and ‘treatment’.</method_desc>
            <param_type>Adjusted Geometric Means ratio</param_type>
            <param_value>104.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.148</ci_lower_limit>
            <ci_upper_limit>110.294</ci_upper_limit>
            <estimate_desc>The estimated value is actually the ratio of Catapres-TTS-3 with Oppanol and Catapres-TTS-3 with Vistanex.
The value in parameter dispersion type and dispersion value is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From patch administration until at most 7 days after patch removal, i.e., up to 14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TTS-3: Oppanol® (T1)</title>
          <description>Administration of TTS-3 with Oppanol®</description>
        </group>
        <group group_id="E2">
          <title>TTS-3: Vistanex™ (R1)</title>
          <description>Administration of TTS-3 with Vistanex™</description>
        </group>
        <group group_id="E3">
          <title>TTS-1: Vistanex™ (R2) + Oppanol® (T2)</title>
          <description>Simultaneous administration of TTS-1 with Oppanol® and TTS-1 with Vistanex™</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Application site papules</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

